Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).
Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade (fast growing) or low grade (slow growing).
Pule and colleagues identify the TCR β-chain constant region as a new target for chimeric
antigen receptor (CAR) T cells in treatment of T cell cancers while potentially preserving a healthy
T cell repertoire. They demonstrate that anti-TCRB1 CAR T cells eliminate cancerous
TCRB1+ T cells while sparing nearly one-third of normal TCRB2+ T cells.
A study in mouse models of allogeneic stem cell transplantation with donor-derived CD19 chimeric antigen receptor (CAR) T cells for the treatment of relapsed B cell malignancies indicates that T cell exhaustion might have a role in preventing allogeneic reactivity of CD19 CAR T cells.
Boice, Salloum, Mourcin et al. show that HVEM is an important tumour suppressor in lymphomas and that direct delivery of a soluble HVEM peptide using engineered T cells might be therapeutically beneficial.